Aurobindo Pharma Gains as USFDA Grants Favorable Report on Chitkul Facility Inspection

9 Jan 2024 , 12:14 PM

Aurobindo Pharma’s share price rises in opening trade on January 9 after receiving a favorable establishment inspection report from the USFDA.

The USFDA inspected the company’s formulation manufacturing facility in Chitkul, Telangana, in September, classifying it as ‘Voluntary Action Indicated’ (VAI) in the report.

VAI indicates that no objectionable conditions were found during the inspection, allowing the facility to function without further regulatory action.

Aurobindo Pharma’s subsidiary, APL Healthcare in Tirupati, also received VAI classification from the USFDA.

In December, the company’s arm Eugia US Manufacturing LLC faced 10 observations from the FDA after a pre-approval inspection at its new injectable facility in East Windsor, New Jersey, USA.

Aurobindo Pharma’s current stock price on the BSE is Rs 1,121.80, reflecting a 0.68 % increase.

The share reached a 52-week high of Rs 1,133.95 on January 8, 2024, and a 52-week low of Rs 397.30 on February 3, 2023.

For feedback and suggestions, write to us at [e-mail]